Endonovo Therapeutics (ENDV) Short term Debt (2016 - 2023)
Endonovo Therapeutics has reported Short term Debt over the past 9 years, most recently at $5.9 million for Q3 2023.
- Quarterly results put Short term Debt at $5.9 million for Q3 2023, up 12.74% from a year ago — trailing twelve months through Sep 2023 was $5.9 million (up 12.74% YoY), and the annual figure for FY2022 was $17.4 million, up 404.29%.
- Short term Debt for Q3 2023 was $5.9 million at Endonovo Therapeutics, roughly flat from $5.9 million in the prior quarter.
- Over the last five years, Short term Debt for ENDV hit a ceiling of $17.4 million in Q4 2022 and a floor of $3.2 million in Q1 2020.
- Median Short term Debt over the past 5 years was $5.3 million (2021), compared with a mean of $6.3 million.
- Biggest five-year swings in Short term Debt: plummeted 60.35% in 2020 and later surged 404.29% in 2022.
- Endonovo Therapeutics' Short term Debt stood at $10.6 million in 2019, then tumbled by 60.35% to $4.2 million in 2020, then decreased by 18.09% to $3.4 million in 2021, then surged by 404.29% to $17.4 million in 2022, then crashed by 66.0% to $5.9 million in 2023.
- The last three reported values for Short term Debt were $5.9 million (Q3 2023), $5.9 million (Q2 2023), and $9.3 million (Q1 2023) per Business Quant data.